Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.585 USD | +3.26% | -3.32% | -46.84% |
Apr. 11 | Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment | MT |
Apr. 11 | Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc | CI |
Financials (USD)
Sales 2024 * | 28.05M | Sales 2025 * | 72.09M | Capitalization | 38.09M |
---|---|---|---|---|---|
Net income 2024 * | -1M | Net income 2025 * | 39M | EV / Sales 2024 * | 1.36 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.53 x |
P/E ratio 2024 * |
230
x | P/E ratio 2025 * |
0.86
x | Employees | 14 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.89% |
Latest transcript on Ocuphire Pharma, Inc.
1 day | +0.33% | ||
1 week | -8.08% | ||
Current month | -23.63% | ||
1 month | -21.68% | ||
3 months | -42.94% | ||
6 months | -44.58% | ||
Current year | -49.00% |
Managers | Title | Age | Since |
---|---|---|---|
George Magrath
CEO | Chief Executive Officer | 40 | Oct. 31 |
Nirav Jhaveri
DFI | Director of Finance/CFO | 46 | Feb. 13 |
Barbara Withers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 20-10-31 |
James Manuso
BRD | Director/Board Member | 75 | 18-12-31 |
Susan Benton
BRD | Director/Board Member | 59 | 20-10-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1.6 | +4.23% | 26 781 |
24-04-25 | 1.535 | +0.33% | 110,754 |
24-04-24 | 1.53 | -0.65% | 89,831 |
24-04-23 | 1.54 | +1.99% | 140,723 |
24-04-22 | 1.51 | -8.76% | 379,231 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.00% | 38.09M | |
+24.98% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.66% | 233B | |
+5.76% | 201B | |
-9.94% | 193B | |
-12.26% | 143B | |
-6.47% | 144B |
- Stock Market
- Equities
- OCUP Stock